Thermo Fisher Scientific’s $13.6bn deal for Life Technologies has been cleared by the EU Commission with conditions.
Clearance is conditional on divestments of businesses producing and supplying media and sera for cell culture, gene silencing products and polymer-based magnetic beads after competition concerns in the European Economic Area (EEA).
Thermo Fisher agreed to divest its HyClone business regarding media and sera for cell culture (excluding single use technologies, where the parties' activities do not overlap).
The gene modulation business in Lafayette, Colorado, US, including the Dharmacon and Open Biosystems brands, equipment, staff and its license regarding the Tuschl patents.
The polymer-based magnetic beads business (including the Sera-Mag brand and other relevant IPRs, customer contracts, personnel and production equipment).
Joaquín Almunia, commission vice president in charge of competition policy said: "The remedies preserve competition and innovation in the life sciences industry.
“The commission's investigation of these complex markets was conducted in close cooperation with a significant number of competition authorities worldwide, such as the US FTC and the Australian ACCC, making this global case a good example of international cooperation."